IGF Recombinant Proteins
Insulin-like Growth Factor (IGF) Recombinant Protein refers to bioengineered proteins closely mimicking the naturally occurring IGF peptides. IGFs, primarily IGF-1 and IGF-2, are growth factors structurally similar to insulin and play critical roles in cellular growth, differentiation, and metabolism. Recombinant IGF proteins are expressed in E. coli or mammalian expression systems, ensuring their bioactivity and stability for diverse research and therapeutic applications.
Content
IGF recombinant proteins are synthesized through recombinant DNA technology, enabling the production of high-purity and bioactive forms of IGF-1 or IGF-2. These proteins maintain the conserved cysteine residues essential for tertiary structure and biological functionality. Recombinant IGF proteins are commonly produced as:
- Human IGF-1 or IGF-2: Mimics endogenous human growth factors.
- Analogues: Modified forms to enhance receptor affinity or prolong half-life.
Manufacturing involves rigorous quality controls, such as endotoxin removal, activity assays, and structural verification via mass spectrometry and HPLC.
Applications
- Cancer Research:
- Investigates IGF-mediated signaling pathways critical in tumorigenesis, angiogenesis, and metastasis.
- Serves as a tool in evaluating IGF receptor-targeted therapies.
- Metabolic and Endocrine Research:
- Models the role of IGF in glucose metabolism, insulin sensitivity, and anabolic growth.
- Assesses therapeutic potential in diabetes and growth hormone disorders.
- Wound Healing and Regeneration:
- Explores IGF’s influence on tissue repair and regenerative medicine due to its ability to stimulate cell migration and extracellular matrix production.
- Drug Discovery and Toxicology:
- Acts as a biomimetic control for receptor-specific drug screening.
- Evaluates potential therapeutic compounds modulating IGF signaling.
Recombinant IGF proteins are indispensable in cutting-edge research, enabling precise modeling of biological systems and therapeutic interventions targeting IGF pathways.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|